Pharmaceutical Gelatin Market Size & Growth Forecast 2027–2036, By Segments (Type, Source, Application, Function), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Pharmaceutical Gelatin Market size was more than USD 1.47 Billion in 2026 and is set to grow at 6.15% CAGR between 2027 and 2036, crossing USD 2.67 Billion by 2036. The industry revenue for 2027 is estimated at USD 1.55 Billion.
Get more details on this report
Request Free Sample ReportPharmaceutical Gelatin Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 41.26% share in 2026, supported by pharmaceutical manufacturing capabilities, established supply chains, and demand for gelatin-based capsules and formulations.
- Asia Pacific is gaining momentum from expanding pharmaceutical production, rising healthcare consumption, growing medicine access, and increasing adoption of oral dosage forms.
Segment Momentum
- The bovine segment accounted for 51.3% share in 2026, supported by broad availability, dependable functional properties, and widespread use in pharmaceutical manufacturing.
- The poultry segment is the fastest-growing source as manufacturers explore alternative gelatin options supported by advances in extraction technologies and evolving supply considerations.
Market Expansion Drivers
- Rising demand for capsules and softgels supporting oral drug delivery expansion
- Expanding chronic disease burden and aging population increasing pharmaceutical consumption
- Growing biologics and vaccine production driving specialized gelatin excipient demand
Leading Market Participants
- Leading companies in the pharmaceutical gelatin market include Gelita AG (Germany), Rousselot (Darling Ingredients) (Netherlands), PB Leiner (Tessenderlo Group) (Belgium), Nitta Gelatin Inc. (Japan), Weishardt Group (France), Lapi Gelatine S.p.A. (Italy), Juncà Gelatines S.L. (Spain), Sterling Biotech Ltd. (India), Xiamen Gelken Gelatin Co., Ltd. (China)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.47 Billion
- 2027 Estimated Market Size: USD 1.55 Billion
- Projected Market Size: USD 2.67 Billion by 2036
- Growth Forecast: 6.15% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Type B (Type) | Bovine (Source) | Capsules (Application) | Stabilizers (Function)
- Emerging Opportunity Segment: Type a (Type) | Poultry (Source) | Capsules (Application) | Gelling Agents (Function)
Market Growth Drivers and Industry Trends
Rising demand for capsules and softgels supporting oral drug delivery expansion
Growing use of oral medicines is sustaining demand for capsule and softgel dosage forms that provide convenient administration and effective delivery of pharmaceutical ingredients. The pharmaceutical gelatin market benefits from this expansion because gelatin offers suitable film-forming, binding, and encapsulation characteristics for hard capsules and softgel shells. Pharmaceutical manufacturers rely on these properties to develop dosage forms that can protect active ingredients, facilitate swallowing, and support controlled handling during manufacturing and packaging. The versatility of gelatin-based capsules across prescription and over-the-counter formulations also enables manufacturers to accommodate a broad range of drug products while maintaining established production processes.
Expanding chronic disease burden and aging population increasing pharmaceutical consumption
The rising prevalence of chronic conditions and continued population aging are increasing the need for long-term medication, expanding the underlying consumption base for pharmaceutical dosage forms. Within the pharmaceutical gelatin market, greater pharmaceutical utilization translates into sustained requirements for capsule shells and other gelatin-based delivery formats used in recurring treatment regimens. Older patients often require multiple medications for conditions managed over extended periods, making convenient and patient-friendly dosage forms particularly important for adherence. Pharmaceutical manufacturers are consequently maintaining significant capsule production capacity to serve therapies spanning cardiovascular, metabolic, neurological, and other chronic disease categories.
Growing biologics and vaccine production driving specialized gelatin excipient demand
Expansion of biologics and vaccine manufacturing is creating additional requirements for pharmaceutical-grade excipients that meet stringent purity, consistency, and formulation specifications. The pharmaceutical gelatin market is supported by gelatin's functional properties as an excipient and processing material in selected pharmaceutical and biological applications, where it can contribute to stabilization, encapsulation, or formulation performance. Increasing complexity in biologic production also raises the importance of materials with consistent quality and tightly controlled characteristics, encouraging manufacturers to source specialized grades suited to pharmaceutical processing requirements. As biologics and vaccine pipelines broaden, demand for high-quality gelatin materials capable of meeting specialized manufacturing standards is increasing.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising demand for capsules and softgels supporting oral drug delivery expansion | 2.2% | High | North America, Europe, Asia Pacific | High | Near Term |
| Expanding chronic disease burden and aging population increasing pharmaceutical consumption | 2% | High | Japan, Europe, North America | High | Mid Term |
| Growing biologics and vaccine production driving specialized gelatin excipient demand | 1.8% | High | Global | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the pharmaceutical gelatin market, accounting for 41.26% in 2026. The region's leading position is supported by a well-developed pharmaceutical industry and consistent demand for gelatin-based capsules and other pharmaceutical formulations. Strong manufacturing capabilities, established pharmaceutical supply chains, and continued demand for convenient drug-delivery formats are contributing to the use of pharmaceutical-grade gelatin. In addition, stringent quality and safety requirements encourage manufacturers to utilize standardized pharmaceutical ingredients, supporting sustained demand for high-quality gelatin across the regional pharmaceutical sector.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to experience the fastest growth in the pharmaceutical gelatin market, driven by expanding pharmaceutical manufacturing, increasing healthcare consumption, and the growing availability of drug products across emerging economies. Rising investments in pharmaceutical production capacity are creating additional demand for pharmaceutical-grade excipients and capsule materials. The region's large and expanding patient population, increasing access to medicines, and development of domestic healthcare and pharmaceutical industries are also supporting market expansion. Growing adoption of oral dosage forms is expected to further strengthen demand for pharmaceutical gelatin across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Advanced Capsule SupplyThe U.S. pharmaceutical gelatin market is driven by demand for hard and soft capsule manufacturing across prescription and nutraceutical products. Manufacturers in the U.S. prioritize consistent raw material quality, regulatory compliance, and dependable domestic supply chains for pharmaceutical production.
Germany 🇩🇪
Quality Manufacturing BaseGermany emphasizes pharmaceutical-grade gelatin production that supports stringent formulation and manufacturing standards. Companies in Germany invest in traceable sourcing and process validation to meet the requirements of pharmaceutical manufacturers and contract development organizations.
Japan 🇯🇵
Precision Formulation SupportJapan relies on pharmaceutical gelatin for high-quality capsule production used in innovative drug formulations. Japanese manufacturers focus on material consistency, product purity, and compatibility with advanced pharmaceutical processing technologies.
South Korea 🇰🇷
Biopharma Production IntegrationSouth Korea strengthens pharmaceutical gelatin demand through expanding pharmaceutical manufacturing and contract production activities. Producers increasingly align gelatin quality with evolving formulation requirements while supporting efficient capsule manufacturing for domestic and export markets.
France 🇫🇷
Regulated Ingredient StandardsFrance supports the pharmaceutical gelatin market through established pharmaceutical manufacturing and rigorous ingredient quality expectations. Market participants prioritize certified sourcing, regulatory compliance, and reliable supply for capsule and specialty dosage form production.
Italy 🇮🇹
Capsule Manufacturing FocusItaly maintains stable demand for pharmaceutical gelatin through its pharmaceutical production and contract manufacturing capabilities. Italian companies emphasize consistent material performance and validated production processes to support efficient capsule manufacturing operations.
Segment Leadership and Growth Trends
Pharmaceutical Gelatin Market Share (%), by Type, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportType Segment Analysis: Type B (Largest Segment) vs Type a (Fastest-Growing Segment)
The type B segment dominated the pharmaceutical gelatin market, accounting for the largest share of 62.78% in 2026. Its leadership is supported by its extensive use in pharmaceutical formulations requiring strong gel strength, consistent viscosity, and reliable film-forming characteristics. Type B gelatin is widely utilized in the production of hard capsules, tablet coatings, and other dosage forms where stability and manufacturing efficiency are critical. Its broad compatibility with pharmaceutical processing techniques and established regulatory acceptance continue to reinforce its dominant position across the industry.
The type A segment is expected to witness the fastest growth as pharmaceutical manufacturers increasingly seek gelatin grades with excellent clarity, rapid dissolution characteristics, and compatibility with advanced drug delivery systems. Rising demand for innovative capsule formulations, expanding biologics production, and continuous product development in oral dosage technologies are contributing to stronger adoption of type A gelatin.
Source Segment Analysis: Bovine (Largest Segment) vs Poultry (Fastest-Growing Segment)
Holding the largest share of 51.3% in 2026, the bovine segment led the pharmaceutical gelatin market due to its broad availability, dependable functional properties, and widespread use in pharmaceutical manufacturing. Bovine-derived gelatin offers excellent performance in capsule production and other pharmaceutical applications while supporting consistent product quality. Continued reliance on established raw material supply chains and increasing demand for high-quality excipients further strengthen the segment's leadership.
The poultry segment is emerging as the fastest-growing source as manufacturers diversify raw material options to meet evolving regulatory, cultural, and supply chain considerations. Growing research into alternative gelatin sources, together with advances in extraction and processing technologies, is improving the commercial viability of poultry-derived gelatin for pharmaceutical applications and expanding its adoption.
Application Segment Analysis: Capsules (Largest & Fastest-Growing Segment)
The capsules segment led the pharmaceutical gelatin market and accounted for the largest share of 43.67% in 2026. Gelatin remains the preferred material for capsule manufacturing because it provides excellent film-forming capability, rapid dissolution, mechanical strength, and compatibility with a wide variety of pharmaceutical ingredients. Increasing demand for oral solid dosage forms, expanding production of prescription and over-the-counter medicines, and continuous innovation in capsule technologies are driving sustained growth in this application. The widespread preference for capsule-based drug delivery systems positions this segment as both the largest and fastest-growing application within the market.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Type | Type A, Type B | Type B | Type a |
| Source | Porcine, Bovine, Fish, Poultry | Bovine | Poultry |
| Application | Capsules, Tablets, Absorbable Hemostats, Others | Capsules | Capsules |
| Function | Stabilizers, Thickeners, Gelling Agents, Film Forming, Adhesion, Others | Stabilizers | Gelling Agents |
Competitive Landscape and Market Positioning
Leading companies in the pharmaceutical gelatin market:
- Gelita AG (Germany)
- Rousselot (Darling Ingredients) (Netherlands)
- PB Leiner (Tessenderlo Group) (Belgium)
- Nitta Gelatin, Inc. (Japan)
- Weishardt Group (France)
- Lapi Gelatine S.p.A. (Italy)
- Juncà Gelatines S.L. (Spain)
- Sterling Biotech Ltd. (India)
- Xiamen Gelken Gelatin Co., Ltd. (China)
Pharmaceutical gelatin suppliers are competing increasingly through quality differentiation, supply reliability, and compliance capabilities rather than basic material availability. Producers with stronger control over sourcing, purification processes, and documentation systems are better positioned as drug manufacturers demand consistent inputs for capsules, coatings, and specialized formulations. Regional suppliers are attempting to expand their presence by improving manufacturing standards and targeting cost-sensitive applications, while established participants are reinforcing relationships with pharmaceutical customers through process expertise and regulatory readiness. Innovation is shifting toward customized gelatin characteristics and alternative formulation support as manufacturers seek materials that align with evolving drug delivery requirements.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Gelita AG (Germany) | |||||||
| Rousselot (Darling Ingredients) (Netherlands) | |||||||
| PB Leiner (Tessenderlo Group) (Belgium) | |||||||
| Nitta Gelatin Inc. (Japan) | |||||||
| Weishardt Group (France) | |||||||
| Lapi Gelatine S.p.A. (Italy) | |||||||
| Juncà Gelatines S.L. (Spain) | |||||||
| Sterling Biotech Ltd. (India) | |||||||
| Xiamen Gelken Gelatin Co. Ltd. (China) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Barentz | Jun-25 | Barentz acquired China-based Fengli Group to strategically expand its distribution network and market presence for pharmaceutical excipients across the Asia-Pacific region, enhancing its operational capabilities in local supply chains. |
| Roquette | May-25 | Roquette completed the acquisition of IFF Pharma Solutions, significantly expanding its manufacturing footprint and production capacity for vegetarian and pharmaceutical capsule alternatives. |
| Nitta Gelatin | May-25 | Nitta Gelatin initiated a ₹60 crore capital expenditure program at its Kerala facility, concentrating on scaling up production capabilities for specialized collagen peptides. |
| Rousselot | Dec-23 | Rousselot secured U.S. Patent No. US11795489B2 for StabiCaps, a specialized gelatin formulation designed to improve soft gel capsule stability and enhance the release profile of active pharmaceutical ingredients. |
| Rousselot | Jan-22 | Rousselot entered into a strategic collaboration with the Terasaki Institute for Biomedical Innovation to advance gelatin-based therapeutic applications using its proprietary X-Pure modified gelatin range. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Pharmaceutical Gelatin Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Grade | Pharmaceutical Grade, High-Purity Grade, Specialized Medical Grade |
| End User | Pharmaceutical Manufacturers, Biopharmaceutical Manufacturers, Medical Device Manufacturers, Contract Manufacturers |
| Sales Channel | Direct Sales, Distributors, Specialty Pharmaceutical Ingredient Suppliers |
Pharmaceutical Gelatin Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Pharmaceutical Supply Security and Sourcing Risk Assessment |
|
| Gelatin Alternatives and Substitution Outlook |
|
| Pharmaceutical Formulation Adoption Pathways |
|
Need a different cut of the data?
Request Custom ResearchWhat is the market size of pharmaceutical gelatin?
What is the expected industry size of pharmaceutical gelatin by 2036?
How is pharmaceutical consumption growth impacting demand for gelatin-based dosage solutions?
How are biologics and vaccine developments influencing pharmaceutical gelatin requirements?
Why does the bovine source segment dominate the pharmaceutical gelatin market?
How is the poultry source segment creating new growth opportunities?
What supports North America's leadership in the pharmaceutical gelatin market?
Why is Asia Pacific expected to grow fastest in pharmaceutical gelatin?
Which organizations are considered leaders in the pharmaceutical gelatin landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization